AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36585956 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes group
Number of subjects: 17
Study 36585956 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic control group
Number of subjects: 17
Study 36586038 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 1709
Study 36586038 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1709
Study 36586038 — intervention group
Group type: COMPARATOR
Intervention: Public healthcare system
Number of subjects: 1709
Study 36586038 — intervention group
Group type: COMPARATOR
Intervention: Private healthcare system
Number of subjects: 1709
Study 36586101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Number of subjects: 8
Study 36586101 — intervention group
Group type: COMPARATOR
Intervention: No Ribavirin (Control)
Number of subjects: 8
Study 36586213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 278
Study 36586351 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate treatment (DMF)
Number of subjects: 42
Study 36586514 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg oral melatonin
Number of subjects: 88
Study 36586514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 36586583 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5%, 0.75%, or 1.5% ruxolitinib cream applied twice daily for 28 days
Number of subjects: 71
Study 36586812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration ≥9 hours
Number of subjects: 1228
Study 36586812 — intervention group
Group type: COMPARATOR
Intervention: Sleep duration 7 to <8 hours
Number of subjects: 1228
Study 36586812 — intervention group
Group type: EXPERIMENTAL
Intervention: Later sleep midpoints (3rd tertile)
Number of subjects: 1228
Study 36586812 — intervention group
Group type: COMPARATOR
Intervention: Later sleep midpoints (2nd tertile)
Number of subjects: 1228
Study 36586812 — intervention group
Group type: EXPERIMENTAL
Intervention: Social jetlag (continuous per hour)
Number of subjects: 1228
Study 36586812 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shift work
Number of subjects: 1228
Study 36586812 — intervention group
Group type: COMPARATOR
Intervention: Non-night shift work
Number of subjects: 1228
Study 36586812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration ≥9 hours (excluding shift workers)
Number of subjects: 1228
Study 36586812 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception sleep
Number of subjects: 1228
Study 36586812 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1228
Study 36587174 — intervention group
Group type: EXPERIMENTAL
Intervention: Theranostic-guided riboflavin/UV-A corneal cross-linking (CXL)
Number of subjects: 50
Study 36587174 — intervention group
Group type: COMPARATOR
Intervention: Epithelium-off or epithelium-on CXL
Number of subjects: 50
Study 36587281 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutrition support
Number of subjects: 517
Study 36587281 — intervention group
Group type: COMPARATOR
Intervention: Usual-care nutrition
Number of subjects: 517
Study 36587281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low prealbumin levels
Number of subjects: 517
Study 36587393 — intervention group
Group type: EXPERIMENTAL
Intervention: nsPEF ablation
Number of subjects: 15
Study 36587547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine supplemented analgesia
Number of subjects: 118
Study 36587801 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with osteoporosis
Number of subjects: 100
Study 36587801 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with osteopenia
Number of subjects: 100
Study 36587801 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women with normal BMD
Number of subjects: 100
Study 36587801 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women with normal BMD
Number of subjects: 100
Study 36587890 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous C.E.R.A. administration every 4 weeks
Number of subjects: 40
Study 36588113 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM treatment (590, 660 and 850 nm) 3 times per week over 3-4 weeks (9 treatments per series)
Number of subjects: 44
Study 36588113 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 44
Study 36588113 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM treatment
Number of subjects: 44
Study 36588113 — intervention group
Group type: COMPARATOR
Intervention: PBM treatment and sham treatment
Number of subjects: 44
Study 36588137 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 172
Study 36588137 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 300 mg
Number of subjects: 172
Study 36588137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 36588166 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 911
Study 36588166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study 36588335 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD-27)
Number of subjects: 0
Study 36588387 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin plus busulfan and cyclophosphamide (IDA-BuCy)
Number of subjects: 154
Study 36588387 — intervention group
Group type: COMPARATOR
Intervention: Busulfan and cyclophosphamide (BuCy)
Number of subjects: 154
Study 36588397 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapies
Number of subjects: 0
Study 36588397 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid conditions
Number of subjects: 0
Study 36588397 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional performance
Number of subjects: 0
Study 36588672 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng Powder
Number of subjects: 0
Study 36588672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36588741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganshuang granule combined with tenofovir; dosage and duration not available
Number of subjects: 0
Study 36588741 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details not available
Number of subjects: 0
Study 36588884 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurohawk retriever
Number of subjects: 232
Study 36588884 — intervention group
Group type: COMPARATOR
Intervention: Solitaire FR
Number of subjects: 232
Study 36589413 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) data analysis
Number of subjects: 211
Study 36589545 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training program (supervised progressive resistance and strength exercise over 3 consecutive days)
Number of subjects: 0
Study 36589545 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36589629 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 16
Study 36589629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 16
Study 36589863 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sets resistance training plus aerobic training
Number of subjects: 84
Study 36589863 — intervention group
Group type: EXPERIMENTAL
Intervention: Single set resistance training plus aerobic training
Number of subjects: 84
Study 36589863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 36589958 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 condition (long COVID)
Number of subjects: 61655
Study 36589958 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR positive test group
Number of subjects: 61655
Study 36589958 — intervention group
Group type: COMPARATOR
Intervention: PCR negative test group
Number of subjects: 61655
Study 36590610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention
Number of subjects: 13
Study 36590610 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 36590621 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 93
Study 36590621 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Intensity Continuous Training (MVCT)
Number of subjects: 93
Study 36590621 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 36590787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg over 40 min)
Number of subjects: 394
Study 36590787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 36590787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 394
Study 36590789 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) once daily for 10 days
Number of subjects: 594
Study 36590789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 36591351 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated segmentation model for kidney and liver in MRI scans
Number of subjects: 327
Study 36591351 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated TKV measurement
Number of subjects: 327
Study 36591351 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated TLV estimation
Number of subjects: 327
Study 36591351 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated TKV for external dataset
Number of subjects: 327
Study 36591610 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised treatments
Number of subjects: 2144
Study 36591610 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy containing metronidazole, tetracycline and bismuth
Number of subjects: 2144
Study 36591610 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple amoxicillin-levofloxacin therapy
Number of subjects: 2144
Study 36591610 — intervention group
Group type: COMPARATOR
Intervention: Overall treatments
Number of subjects: 2144
Study 36591610 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence of adverse events
Number of subjects: 2144
Study 36591612 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 883
Study 36591612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 883
Study 36591636 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing acceptance and commitment therapy (ACT)
Number of subjects: 19
Study 36591636 — intervention group
Group type: COMPARATOR
Intervention: Control group (psychoeducation materials only)
Number of subjects: 19
Study 36591795 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography-derived respiratory indices during inpatient acute rehabilitation
Number of subjects: 66
Study 36591795 — intervention group
Group type: COMPARATOR
Intervention: Chronic pain status assessment at 1- to 2-year follow-up
Number of subjects: 66
Study 36591808 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative transvaginal ultrasonography
Number of subjects: 1079
Study 36592299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cephalexin (1000 mg)
Number of subjects: 33
Study 36592299 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cephalexin (500 mg)
Number of subjects: 33
Study 36592498 — intervention group
Group type: EXPERIMENTAL
Intervention: PLCOm2012 risk model
Number of subjects: 0
Study 36592505 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid 6-monthly (≤6 infusions, n=170)
Number of subjects: 1803
Study 36592505 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid 6-monthly (≥7 infusions, n=555)
Number of subjects: 1803
Study 36592507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg every 6 weeks for a maximum of two infusions), Nivolumab (6 mg/kg every four weeks), Tocilizumab (8 mg/kg every four weeks), and SBRT (15 Gy on day one of the first cycle)
Number of subjects: 26
Study 36592507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab, Nivolumab, Tocilizumab, and SBRT
Number of subjects: 26
Study 36592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced self-regulation condition (ESR)
Number of subjects: 136
Study 36592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation condition (SR)
Number of subjects: 136
Study 36592575 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 136
Study 36592649 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for evaluating endometriosis
Number of subjects: 345
Study 36592649 — intervention group
Group type: EXPERIMENTAL
Intervention: Age distribution analysis
Number of subjects: 345
Study 36592649 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale for pain severity
Number of subjects: 345
Study 36592649 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine contractions visualization
Number of subjects: 345
Study 36592688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 14
Study 36592688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 36592818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led task-shifting and mobile health application (Medtronic® Labs' Empower Health), home BP monitoring
Number of subjects: 240
Study 36592818 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus short text messages on health (enhanced usual care arm)
Number of subjects: 240
Study 36592878 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalunfiban dose 1 (0.110 mg/kg)
Number of subjects: 2499
Study 36592878 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalunfiban dose 2 (0.130 mg/kg)
Number of subjects: 2499
Study 36592878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499
Study 36592878 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalunfiban (both doses)
Number of subjects: 2499
Study 36593070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib monotherapy
Number of subjects: 0
Study 36593070 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib combined with gemcitabine and nab-paclitaxel
Number of subjects: 0
Study 36593094 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of TMAO (highest tertile)
Number of subjects: 2379
Study 36593094 — intervention group
Group type: COMPARATOR
Intervention: Baseline TMAO tertiles
Number of subjects: 2379
Study 36593119 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nicotine lactate
Number of subjects: 116
Study 36593119 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% nicotine lactate
Number of subjects: 116
Study 36593119 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nicotine benzoate
Number of subjects: 116
Study 36593119 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% nicotine benzoate
Number of subjects: 116
Study 36593119 — intervention group
Group type: COMPARATOR
Intervention: Free-base nicotine
Number of subjects: 116
Study 36593119 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% vs 50% nicotine lactate
Number of subjects: 116
Study 36593119 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% vs 50% nicotine benzoate
Number of subjects: 116
Study 36593127 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP plus LHE-delivered information session
Number of subjects: 72
Study 36593127 — intervention group
Group type: COMPARATOR
Intervention: SCP alone
Number of subjects: 72
Study 36593181 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard psychosocial intervention delivered in a child-friendly space (CFS) for 12 weeks
Number of subjects: 1280
Study 36593181 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit for Child-Friendly Spaces in Humanitarian Settings for 12 weeks
Number of subjects: 1280
Study 36593181 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1280
Study 36593652 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (VarV) and inactivated hepatitis A vaccine (HepA) co-administered (Group A)
Number of subjects: 450
Study 36593652 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) - VarV and HepA administered separately
Number of subjects: 450
Study 36593702 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly umbilical artery Doppler ultrasound
Number of subjects: 292
Study 36593702 — intervention group
Group type: COMPARATOR
Intervention: Bi-weekly umbilical artery Doppler ultrasound
Number of subjects: 292
Study 36593729 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering in patients receiving subcutaneous daratumumab
Number of subjects: 0
Study 36593729 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous daratumumab
Number of subjects: 0
Study 36593888 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with Yttrium-90 resin microspheres
Number of subjects: 422
Study 36593888 — intervention group
Group type: EXPERIMENTAL
Intervention: Partition model dosimetry
Number of subjects: 422
Study 36594077 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm-bolus on alternate days (SR group)
Number of subjects: 58
Study 36594077 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm-bolus daily (HR group)
Number of subjects: 58
Study 36594077 — intervention group
Group type: COMPARATOR
Intervention: No bolus (SR group)
Number of subjects: 58
Study 36594077 — intervention group
Group type: COMPARATOR
Intervention: 5 mm-bolus on alternate days (HR group)
Number of subjects: 58
Study 36594077 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year local control (SR group)
Number of subjects: 58
Study 36594077 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year local control (HR group)
Number of subjects: 58
Study 36594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall radiodermatitis burden
Number of subjects: 58
Study 36594167 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin in combination with venetoclax and an anti-CD20 antibody
Number of subjects: 50
Study 36594181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 36594181 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 36594185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with Triplex (5.1 × 10^8 pfu)
Number of subjects: 17
Study 36594185 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 36594212 — intervention group
Group type: EXPERIMENTAL
Intervention: D-β-hydroxybutyrate
Number of subjects: 0
Study 36594231 — intervention group
Group type: EXPERIMENTAL
Intervention: WE CARE Houston social needs intervention (screener and resource referrals based on screening results and receptiveness to help)
Number of subjects: 413
Study 36594231 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 413
Study 36594428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (LPD) (0.6 to 0.8 g/kg/day)
Number of subjects: 486
Study 36594428 — intervention group
Group type: COMPARATOR
Intervention: Usual or unrestricted protein diet (UPD) (≥ 1.0 g/kg/day)
Number of subjects: 486
Study 36594430 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole added to venlafaxine XR
Number of subjects: 178
Study 36594430 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to venlafaxine XR
Number of subjects: 178
Study 36594748 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted TME (R-TME)
Number of subjects: 295
Study 36594748 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy-assisted TME (L-TME)
Number of subjects: 295
Study 36594752 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma question prompt list/video intervention
Number of subjects: 189
Study 36594814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue applied to iatrogenic ulcers after standard ESD
Number of subjects: 247
Study 36594814 — intervention group
Group type: COMPARATOR
Intervention: Standard ESD (Control)
Number of subjects: 247
Study 36594820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 261
Study 36594820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 261
Study 36594820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 261
Study 36594820 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime, Ceftriaxone, Ciprofloxacin
Number of subjects: 261
Study 36594835 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional convolutional neural network (CNN) using quantitative ultrasound (QUS) parameters (tissue attenuation imaging [TAI] and tissue scatter-distribution imaging [TSI]) and B-mode images
Number of subjects: 173
Study 36594835 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual scoring of hepatic steatosis on B-mode images
Number of subjects: 173
Study 36594835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue attenuation imaging (TAI)
Number of subjects: 173
Study 36594835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue scatter-distribution imaging (TSI)
Number of subjects: 173
Study 36594947 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (3 to 4 μg/kg); n=575
Number of subjects: 1150
Study 36594947 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular blockers (1 mg/kg of succinylcholine or rocuronium); n=575
Number of subjects: 1150
Study 36594947 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (3 to 4 μg/kg); n=565 (per-protocol population)
Number of subjects: 1150
Study 36594947 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular blockers (1 mg/kg of succinylcholine or rocuronium); n=565 (per-protocol population)
Number of subjects: 1150
Study 36594987 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity score 5 (mechanical ventilation)
Number of subjects: 1508
Study 36594987 — intervention group
Group type: COMPARATOR
Intervention: Severity score 2 (no oxygen therapy)
Number of subjects: 1508
Study 36595042 — intervention group
Group type: EXPERIMENTAL
Intervention: TAB008
Number of subjects: 549
Study 36595042 — intervention group
Group type: COMPARATOR
Intervention: Avastin
Number of subjects: 549